https://www.selleckchem.com/pr....oducts/l-alpha-phosp
7% of recipients and 51% of donors received treatment. Median days of therapy pre-HSCT was 70 days in recipients and 48 days in donors. Post-HSCT ATBI incidence at 1-year follow-up was 0%. CONCLUSIONS LTBI in our population was higher than expected and may still be underestimated due to diagnostic test limitations. Absence of incident ATBI suggests that recipients, as opposed to donors, must receive LTBI treatment. Prevention of infectious complications within the HSCT population should be highly prioritized to impro
Like
Comment
Share
